Collegium Provides 2025 Financial Guidance and Business Update

Core Insights - Collegium Pharmaceutical, Inc. has announced its financial guidance for 2025, projecting product revenues between $735 million and $750 million, with adjusted EBITDA expected to be in the range of $435 million to $450 million, and adjusted operating expenses anticipated between $220 million and $230 million [1][6][4] Financial Guidance for 2025 - The company expects Jornay PM net revenue to exceed $135 million in 2025, driven by its strategic focus on commercial expansion and targeted investments in the product [2][6] - Adjusted EBITDA is projected to be between $435 million and $450 million, while adjusted operating expenses are expected to range from $220 million to $230 million [1][6] Recent Business Highlights - Collegium completed the integration of Ironshore Therapeutics and saw an increase in average weekly prescriptions for Jornay PM during the 2024 back-to-school season [6] - The company repurchased $60 million in shares as part of its $150 million share repurchase program [6] Company Strategy - Collegium aims to build a diversified biopharmaceutical company focused on improving the lives of individuals with serious medical conditions, with a leading portfolio in pain management and a new presence in neuropsychiatry through Jornay PM [5][2] - The company is committed to disciplined capital deployment to create long-term shareholder value while maximizing performance across its entire portfolio [2][5]